Skip to content

Study · Other design · 2017

7 results

Structure-activity relationship for peptídic growth hormone secretagogues.

Ferro P, Krotov G, Zvereva I, Rodchenkov G, Segura J

Drug testing and analysis26 Jan 2016Cited by 12 (Europe PMC)

PMID26811125 (opens in a new tab)DOI10.1002/dta.1947 (opens in a new tab)PepBankPUB-26811125
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 2 results from people.

  1. 01HumanOther designActivity measurement

    After nasal administration of GHRP‑2, receptor assay activity was confirmed in samples from excretion studies, so GHSR1a binding was detectable in excreted urine.

    In plain wordsAfter GHRP‑2 was given through the nose, urine samples still showed activity at the growth hormone secretagogue receptor.

    Peptide
    GHRP-2
    Outcome
    Not applicableGHSR1a binding activity in excreted urine after nasal dosing
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated · nasalAs given in this study.

    Source sentences

    Summary
    To test in vivo the applicability of the activities observed, the receptor assay activity in samples from excretion studies performed after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin was confirmed.
    1 context sentence
    Summary · context
    Overall results obtained allow to infer structure-activity information for those GHRPs and to detect GHSR1a binding (intact GHRPs plus active metabolites) in excreted urines.
  2. 02HumanOther designActivity measurement

    After nasal administration of Hexarelin, receptor assay activity was confirmed in samples from excretion studies, so GHSR1a binding was detectable in excreted urine.

    In plain wordsAfter hexarelin was given through the nose, urine samples still showed activity at the growth hormone secretagogue receptor.

    Peptide
    Hexarelin
    Outcome
    Not applicableGHSR1a binding activity in excreted urine after nasal dosing
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated · nasalAs given in this study.

    Source sentences

    Summary
    To test in vivo the applicability of the activities observed, the receptor assay activity in samples from excretion studies performed after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin was confirmed.
    1 context sentence
    Summary · context
    Overall results obtained allow to infer structure-activity information for those GHRPs and to detect GHSR1a binding (intact GHRPs plus active metabolites) in excreted urines.
  3. 03LabOther designActivity measurement

    Receptor assay activity at GHSR1a was confirmed in urine samples from excretion studies after nasal administration of several GHRPs, including ipamorelin.

    In plain wordsIn lab tests, urine collected after nasal ipamorelin and other GHRPs showed activity at the ghrelin receptor.

    Peptide
    Ipamorelin
    Outcome
    Not applicableGHSR1a binding activity in urine after nasal administration
    Study

    n: not reported in source

    Urine samples from excretion studies, GHSR1a radio-competitive assay
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated · nasalAs given in this study.

    Source sentences

    Summary
    To test in vivo the applicability of the activities observed, the receptor assay activity in samples from excretion studies performed after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin was confirmed.
    1 context sentence
    Summary · context
    Overall results obtained allow to infer structure-activity information for those GHRPs and to detect GHSR1a binding (intact GHRPs plus active metabolites) in excreted urines.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 04LabNot a test of GHRP-6 aloneIn vitro (cell-free)Activity measurement

    In a GHSR1a radio-competitive assay, chemical modifications at positions 1, 2, 3 and 7 of GHRPs with the Ala-Trp-(D-Phe)-Lys core influenced receptor activity.

    In plain wordsIn lab tests, changes at four positions in growth hormone releasing peptides altered how they bind the ghrelin receptor GHSR1a.

    Peptide
    GHRP-6
    Outcome
    Not applicableGHSR1a binding structure-activity of GHRPs
    Study

    n: not reported in source

    GHSR1a radio-competitive binding assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Several GHRPs and truncated analogues with the common core Ala-Trp-(D-Phe)-Lys have been studied with a radio-competitive assay for the GHSR1a receptor against the radioactive natural ligand ghrelin.
    1 context sentence
    Summary · context
    Relevant chemical modifications influencing the activity for positions 1, 2, 3, and 7 based on the structure aa-aa-aa-Ala-Trp-(D-Phe)-Lys have been obtained.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 05LabNot a test of GHRP-6 aloneIn vitro (cell-free)Activity measurement

    A receptor assay confirmed GHSR1a binding activity in urine samples after nasal administration of GHRP-1, GHRP-2, GHRP‑6, hexarelin and ipamorelin pooled.

    In plain wordsIn lab tests, urine from nasal use of several growth hormone releasing peptides, GHRP‑6 among them, still bound the ghrelin receptor.

    Peptide
    GHRP-6
    Outcome
    Not applicableGHSR1a binding activity in urine after nasal administration of GHRPs
    Study

    n: not reported in source

    GHSR1a receptor assay on excreted urine
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    To test in vivo the applicability of the activities observed, the receptor assay activity in samples from excretion studies performed after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin was confirmed.
    1 context sentence
    Summary · context
    Overall results obtained allow to infer structure-activity information for those GHRPs and to detect GHSR1a binding (intact GHRPs plus active metabolites) in excreted urines.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 06LabNot a test of GHRP-2 aloneIn vitro (cell-free)Activity measurement

    In a GHSR1a competitive binding assay, chemical modifications at positions 1, 2, 3 and 7 of GHRPs with the Ala-Trp-(D-Phe)-Lys core changed receptor binding activity.

    In plain wordsIn lab tests, changing certain amino acids in growth hormone-releasing peptides altered how well they bound the receptor.

    Peptide
    GHRP-2
    Outcome
    Not applicableStructure-activity of GHRP core at GHSR1a
    Study

    n: not reported in source

    GHSR1a radio-competitive binding assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Relevant chemical modifications influencing the activity for positions 1, 2, 3, and 7 based on the structure aa-aa-aa-Ala-Trp-(D-Phe)-Lys have been obtained.
    1 context sentence
    Summary · context
    Several GHRPs and truncated analogues with the common core Ala-Trp-(D-Phe)-Lys have been studied with a radio-competitive assay for the GHSR1a receptor against the radioactive natural ligand ghrelin.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 07LabNot a test of Hexarelin aloneIn vitro (cell-free)Activity measurement

    In a GHSR1a competitive binding assay, chemical modifications at positions 1, 2, 3 and 7 of GHRPs with the Ala-Trp-(D-Phe)-Lys core changed receptor binding activity.

    In plain wordsIn lab tests, changing certain amino acids in growth hormone-releasing peptides altered how well they bound the receptor.

    Peptide
    Hexarelin
    Outcome
    Not applicableStructure-activity of GHRP core at GHSR1a
    Study

    n: not reported in source

    GHSR1a radio-competitive binding assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Relevant chemical modifications influencing the activity for positions 1, 2, 3, and 7 based on the structure aa-aa-aa-Ala-Trp-(D-Phe)-Lys have been obtained.
    1 context sentence
    Summary · context
    Several GHRPs and truncated analogues with the common core Ala-Trp-(D-Phe)-Lys have been studied with a radio-competitive assay for the GHSR1a receptor against the radioactive natural ligand ghrelin.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 23 to 46Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 24 times, first on 13 Oct 2026, 21:43 UTC. The status did not change between them.

    Study results updated

  2. Versions 21 to 22

    13 Oct 2026, 16:31 UTC

    The same notice was added 2 times, first on 13 Oct 2026, 16:31 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Versions 3 to 20

    13 Oct 2026, 14:22 UTC

    The same notice was added 18 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  4. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.